Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gyneco
- PDF / 479,023 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 24 Downloads / 194 Views
ORIGINAL ARTICLE
Bevacizumab‑associated events in Japanese women with cervical cancer: a multi‑institutional survey of Obstetrical Gynecological Society of Kinki district, Japan Seiji Mabuchi1 · Misa Yamamoto2 · Hiroko Murata3 · Takuya Yokoe4 · Junzo Hamanishi5 · Yoshito Terai6 · Hikaru Imatake7 · Yasushi Mabuchi8 · Taisuke Mori9 · Fuminori Kitada10 · Yasuhiro Hashiguchi11 · Akimasa Takahashi12 · Satoe Fujiwara13 · Hirokazu Naoi14 · Sho Matsubara1 Received: 21 July 2020 / Accepted: 23 October 2020 © Japan Society of Clinical Oncology 2020
Abstract Background The development of perforations or fistulas in the Gastrointestinal (GI) tract or genitourinary (GU) system is a serious adverse effect of bevacizumab. The aim of this study was to investigate the incidences of these GI/GU events as well as their association with previous radiotherapy (RT) in Japanese women with cervical cancer. Methods We conducted a written questionnaire survey among 14 gynecological institutions belonging to the Oncology Research Committee of the Obstetrical and Gynecological Society of Kinki District, Japan. The severity of GI/GU events was classified according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0. All data were extracted from survey responses and maintained in an Excel spreadsheet and summarized using descriptive statistics. Results The information of 224 Japanese women with cervical cancer (152 recurrent and 72 advanced) who were treated with bevacizumab-containing chemotherapy was collected from 14 institutions. Of these, 65% had been previously treated with RT. GI/GU events of any grade developed in 25 (11.2%) patients, leading directly to death in 3 (1.3%) patients. When compared, the incidence of GI/GU events was higher in recurrent disease patients than in advanced disease patients (13.8% vs 5.6%, p = 0.0728). When examined according to the history of RT, the incidence of GI/GU events was greater in patients with a history of RT than in those without (14.5% vs 5.1%, p = 0.044). Conclusion More than 10% of patients experience GI/GU events during or after receiving bevacizumab-containing chemotherapies. Prior RT is a risk factor for bevacizumab-associated GI/GU events. Keywords Cervical cancer · Bevacizumab · Perforation · Fistula · Risk factor
Introduction It is estimated that approximately 30–35% of patients with invasive cervical cancer will develop recurrent or persistent disease after the primary treatment, and recurrent cervical cancer patients have a dismal prognosis, with a reported 2-year survival rate of approximately 15–20% [1, 2]. Platinum-based combination chemotherapy has been Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10147-020-01826-3) contains supplementary material, which is available to authorized users. * Seiji Mabuchi smabuchi@naramed‑u.ac.jp Extended author information available on the last page of the article
the main treatment for patients with recurrent or advanced cervical cancer that are n
Data Loading...
